Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 8/20 | 0.34 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
| ▸ | WEE1 | P30291 | 1/20 | 0.32 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.32 |
| ▸ | STK4 | Q13043 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035526 | 0.82 | TNK2 (0.35) | TNK2EGFR | |
| SCHEMBL15035425 | 0.81 | EGFR (0.32) | TNK2EGFRAURKACDK4 | |
| SCHEMBL15041562 | 0.80 | CDK4 (0.47) | AURKACDK4JAK3 | |
| SCHEMBL15035506 | 0.67 | TYRO3 (0.36) | NUAK1AURKAJAK3 | |
| SCHEMBL15035264 | 0.66 | CDK4 (0.51) | TNK2EGFRAURKACDK4JAK3 | |
| SCHEMBL15035288 | 0.66 | NUAK1 (0.37) | NUAK1CDK4JAK3 | |
| SCHEMBL15035284 | 0.66 | CDK4 (0.51) | TNK2EGFRAURKACDK4JAK3 | |
| SCHEMBL15041360 | 0.66 | CDK4 (0.46) | AURKACDK4JAK3 | |
| SCHEMBL15041305 | 0.66 | CDK4 (0.46) | AURKACDK4JAK3 | |
| SCHEMBL15035356 | 0.65 | CDK4 (0.38) | TNK2NUAK1AURKACDK4JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | TNK2 7/4885DCLK1 539/4885LRRK2 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.